Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 3
Submit an article Journal homepage
654
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Research

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

Elisabet E. ManasanchMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ;Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Carlos Fernández de LarreaMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ;Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona. Institut D’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain;
,
Adriana ZingoneMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Seth M. SteinbergBiostastistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Mary KwokMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Nishant TagejaMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Manisha BhutaniMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Dickran KazandjianMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Mark RoschewskiMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Peter WuMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
George CarterMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Diamond ZuchlinskiMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Marcia MulquinMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Liz LampingMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Rene CostelloMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Deborah BurtonMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Lindsay A. GilMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
William D. FiggMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Irina MaricLaboratory of Hematology, Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, USA;
,
Katherine R. CalvoLaboratory of Hematology, Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, USA;
,
Constance YuanFlow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Maryalice Stetler-StevensonFlow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Neha KordeMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ;Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
&
Ola LandgrenMultiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ;Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
 show all
Pages 639-645 | Received 12 Feb 2016, Accepted 07 Jul 2016, Published online: 09 Aug 2016

References

  • Manasanch EE, Korde N, Zingone A, et al. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma. 2014;55:1707–1714.
  • Richardson PG, Xie W, Jagannath S, et al. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461–1469.
  • Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–686.
  • Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–1809.
  • Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood. 2007;109:2100–2105.
  • Ma W, Kantarjian H, O'Brien S, et al. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008;112:1306–1312.
  • Ma W, Kantarjian H, Bekele B, et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009;15:3820–3826.
  • Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–754.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
  • Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry Part B, Clin Cytom. 2011;80:83–90.
  • Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Res. 2014;38:371–376.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457–481.
  • International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
  • Greenberg AJ, Rajkumar SV, Therneau TM, et al. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28:398–403.
  • Ocio EM, Mitsiades CS, Orlowski RZ, et al. Future agents and treatment directions in multiple myeloma. Exp Rev Hematol. 2014;7:127–141.
  • Wada M, Kosaka M, Saito S, et al. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med. 1993;121:215–223.
  • Ostrowska H, Hempel D, Holub M, et al. Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem. 2008;41:1377–1383.
  • Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383–6391.
  • Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126:2366–2369.
  • Roth GA, Moser B, Krenn C, et al. Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest. 2005;35:399–403.
  • Egerer K, Kuckelkorn U, Rudolph PE, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol. 2002;29:2045–2052.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.